Title: Nanotechnology-Based Innovations in Chronic Obstructive Pulmonary Disease (COPD) Treatment and Management
Publisher: Academic Pr
Publication Date: 2026
Language: English
ISBN 10: 044343946X
ISBN 13: 9780443439469
Binding: Paperback
Condition: Brand New
Weight: 0.9 kilograms

About this title

Synopsis

Nanotechnology-Based Innovations in Chronic Obstructive Pulmonary Disease (COPD) Treatment and Management explores innovative drug delivery systems utilizing nanotechnology to revolutionize the treatment and management of COPD. By presenting the latest advancements in nanotechnologies―including polymeric nanoparticles, liposomes, and theranostic nanoparticles―this volume aims to enhance patient outcomes, alleviate symptoms, and improve lung function, thereby addressing the urgent need for more effective therapies. Structured to cater to a diverse audience, from beginners to advanced researchers, this comprehensive text begins with an overview of COPD, its epidemiology, and current limitations in treatment. The core chapters explore a wide range of nanotechnological applications for diagnosis and disease management, including cutting-edge topics such as nano-immunotherapy and green nanotechnology. Each chapter was developed by a multidisciplinary team of experts from academia and industry, ensuring a comprehensive approach that integrates insights from pharmaceutical sciences, respiratory health, and bioinformatics. Nanotechnology-based Innovations in Chronic Obstructive Pulmonary Disease (COPD) Treatment and Management not only fills a critical gap in COPD literature but also serves as an invaluable resource for researchers, clinicians, and students alike. It promises to be a definitive guide on how innovative drug delivery systems can transform COPD care, paving the way for future advancements in respiratory health management.

Highlights cutting-edge nanotechnologies transforming COPD treatment and management for improved patient outcomes
Discusses future directions and challenges in nanotechnology applications for COPD management
Serves as a valuable resource for researchers, clinicians, and students in respiratory health fields
Offers comprehensive coverage of innovative drug delivery systems for effective COPD diagnosis and therapy
Integrates multidisciplinary insights from experts in pharmaceutical sciences, respiratory health, and bioinformatics

About the Authors

Dr. Harish Dureja is Professor and Head, Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak. Dr. Dureja is also the Director, Centre for IPR Studies and Director, Professional Consultancy Cell. Dr. Dureja has more than 22 years of teaching experience. He also holds 18 years research experience in the field of nanoparticulate drug delivery, regulatory affairs and in silico ADME modeling. Dr. Dureja has been awarded with Gold-Medal for the best Ph.D. thesis and research projects worth 1.2 Crore from various funding agencies. He has filed an Indian patent and written a book and authored more than twenty five book chapters. He has published 265 publications in various international and national journals of repute. He worked as Chairman-Scientific Services Committee (LOC) during 69th IPC at Chitkara University, Raj-pura. He also worked as content writer for e-Pathashala program of Ministry of Human Resources Development for Post Graduate course of Pharmaceutical Sciences for the paper novel drug delivery system. He has delivered more than 180 invited Lectures in various conferences, seminars and symposiums and has guided 60 PG scholars and 10 students for doctoral work. He has been awarded the Gold-Medal for Best Ph.D. Thesis, Best Paper Award - Prof. M.L. Khorana Memorial Prize Award – 2005 and Dr. R.L. Nicore award - 2018. He has published six special issues as a Guest Editor for the Journals published by Bentham Science Publishers, and one issue published by Frontiers, Switzerland. He is currently also serving as President, Association of Pharmaceutical Teachers of India (APTI), Haryana State Branch.

Dr Ronan MacLoughlin, PhD MBS, is currently director of Research and Development, Science and Emerging Technologies in Aerogen limited and Irish medical device company specializing in respiratory drug delivery. He has more than 25 years of experience in the design and development of aerosol drug delivery systems and drug/device combination products. He currently has more than 120 articles, and multiple conference presentations and conference papers combined with several patents. He holds the position of adjunct associate professor in Trinity College Dublin’s (Ireland) Department of Pharmaceutics and Pharmaceutical Technology, honorary Senior Lecturer in the Royal College of Surgeons Ireland (RCSI), nonexecutive director on the board of several startup and scaling Med tech and pharmaceutical companies. Additionally, he is currently chair of the pediatric and cystic fibrosis working group within the International Society for aerosols in medicine. In 2024 he was honored with the Thomas T Mercer award, recognizing Dr MacLoughlin’s excellence in the areas of pharmaceutical aerosols and inhalable materials.development of drug delivery systems and drug device combinations, he has >220 collaborative publications,
as well as 12 granted patents.

His most recent focus has been on enabling several clinical programs making use of aerosolised prophylactics
and therapeutics for COVID-19, and his work on delivery of inhaled vaccines has resulted in the
world’s first approval for an orally inhaled vaccine for COVID-19 (Convidecia Air). His contribution to the
state of the art in fugitive medical and patient-derived aerosols was central to the evolution of several
critical care consensus statements around the safe use of aerosol therapy during the COVID-19 pandemic.

Dr. John I. Disouza is a Professor in Pharmaceutics, and Principal, at Tatyasaheb Kore College of Pharmacy, Warananagar, India. He has 20 years of teaching and research experience. Prof. Disouza has published more than 100 research papers, 3 books, and 8 book chapters. He is chief editor of the journal ‘Pharmacumconsequat’ and editor for Centum, and has also served as a guest editor for DDTR. Prof. Disouza is the chairperson of the IPA-Education division for Maharashtra state, a member of the Executive Board of the national IPA-Education division, and EC member of Controlled Release Society- Indian Chapter.

Muralikrishnan Dhanasekaran, is a Professor of Pharmacology and Toxicology at the Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University. He earned his Ph.D. in 1999 from the Jadavpur University, India, in neuropharmacology. From 1999-2001, he became a post-doctoral fellow at the University of Nebraska Medical Center, Omaha, Nebraska, and the Uni-versity of North Dakota School of Medicine and Health Sciences, Grand Forks, ND. He served as a re-search instructor of pharmacology at Texas A & M Health Sciences, Temple, TX. His major area of teaching and research is related to pathophysiology, pharmacology, and toxicology in dementia, movement disorders, addiction (substances of abuse-designer drugs, nicotine, alcohol), hyperglycemia, epilepsy, and aging. His research was funded by the Alzheimer’s Association and Pharmaceutical com-panies in the USA. He has over one hundred and thirteen peer-reviewed publications, fifty book chap-ters, and around four hundred abstracts in national and international meetings in the area of pharma-cology, toxicology, and natural bioactives. He has received several awards for teaching, service, and outreach. He has been an editor or on the editorial board for several books and journals including nat-ural products, pharmacology, toxicology, and neuropharmacology.

Kamal Dua is a Professor in the NICM Health Research Institute and the School of Science at Western Sydney University (WSU). Dr Dua has been recognised and named as one of Australia’s Top 250 researchers in 2026, 2025 and 2024 in Research Magazine by “The Australian� in the research discipline of Health and Medical sciences, and #1/research leader in the area of Pharmacology and Pharmacy (2026, 2025) and Toxicology (2024) respectively. With over 17 years of research experience, he has specialised in drug delivery targeting inflammatory diseases. Additionally, Dr Dua also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. Dr Dua’s research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. Dr Dua’s research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specialises in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.

"About this title" may belong to another edition of this title.

Store Description

Visit Seller's Storefront

Seller's business information

Edward Bowditch Ltd
Exstowe, Exton, Exeter, EX3 0PP, United Kingdom

Sale & Shipping Terms

Terms of Sale

Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch

Right of cancellation

If you are a consumer you can cancel the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.

INFORMATION REGARDING THE RIGHT OF CANCELLATION

Statutory Right to cancel

You have the right to cancel this contract within 14 days without giving any reason.

The cancellation period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the the last good or the last lot or piece.

To exercise the right to cancel, you must inform us, Revaluation Books, Exstowe, Exton, EX3 0PP, Exeter, United Kingdom, 44 1179083586, of your decision to cancel this contract by a clear statement (e.g. a letter sent by post, fax or e-mail). You may use the attached model cancellation form, but it is not obligatory. You can also electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". If you use this option, we will communicate to you an acknowledgement of receipt of such a cancellation on a durable medium (e.g. by e-mail) without delay.

To meet the cancellation deadline, it is sufficient for you to send your communication concerning your exercise of the right to cancel before the cancellation period has expired.

Effects of cancellation

If you cancel this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).

We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.

We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to cancel with contract.

We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.

We may withhold reimbursement until we have received the goods back or you have supplied evidence of having sent back the goods, whichever is the earliest.

You shall send back the goods or hand them over to us or Revaluation Books, Edward Bowditch Ltd, Clifton Heights, Triangle West, BS8 1EJ, Bristol, United Kingdom, 44 1179083586, without undue delay and in any event not later than 14 days from the day on which you communicate your cancellation from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.

Exceptions to the right of cancellation

The right of cancellation does not apply to:

the delivery of newspapers, journals or magazines with the exception of subscription contracts; and
the supply of digital content (including ebooks) which is not supplied on a tangible medium (e.g. on a CD or DVD) if you accepted when you placed your order that we could start to deliver it, and that you could not cancel it once delivery had started.

Model withdrawal form

(complete and return this form only if you wish to withdraw from the contract)

To: (Revaluation Books, Exstowe, Exton, EX3 0PP, Exeter, United Kingdom, 44 1179083586)

I/We (*) hereby give notice that I/We (*) withdraw from my/our (*) contract of sale of the following goods (*)/for the provision of the following goods (*)/for the provision of the following service (*),

Ordered on (*)/received on (*)

Name of consumer(s)

Address of consumer(s)

Signature of consumer(s) (only if this form is notified on paper)

Date

* Delete as appropriate.

Shipping Terms

Orders usually dispatched within two working days.

Shipping rates from United Kingdom to U.S.A.

Shipping rates from United Kingdom to U.S.A.
Order quantity	7 to 14 business days	2 to 3 business days
First item	� 12.50	� 25.00

Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.